Corbus Pharmaceuticals Announces Completion of Phase 2 Study of Resunab for Systemic Sclerosis
Corbus Pharmaceuticals Holdings, Inc. (CRBP), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it has completed the Phase 2 study evaluating Resunab for the treatment of diffuse cutaneous systemic sclerosis (“systemic sclerosis”). Corbus expects to report topline data from this study in the fourth quarter of 2016. Read more >>